Sort
48,018 grants matching “immunotherapy”
OSTEOGENIC AND IMMUNOMODULATORY PROPERTIES OF DECIDUOUS TOOTH STEM CELLS
$400,000Songtao Shi · University Of Pennsylvania · R01 · FY2015 · DE
Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment
$400,000Adam Shilling · Nanocan Therapeutics Corporation · R41 · FY2022 · CA
Regulation and function of nonlymphoid organ CD103 dendritic cells
$400,000Stephanie S Watowich · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · AI
Immunopathogenesis of Toxoplasmic encephalitis
$400,000Christopher A Hunter · University Of Pennsylvania · R01 · FY2017 · AI
High-throughput Label-free Biosensor Platform for Rapid Detection of Antigen-specific T Cells with Single Cell Resolution
$400,000Farshid Ghasemi · Weddell Technologies Llc · R43 · FY2021 · CA
Enzymology of Mismatch Repair in Yeast
$400,000Richard D Kolodner · Ludwig Institute For Cancer Res Ltd · R01 · FY2019 · GM
Signaling functions of Peli family of E3 ubiquitin ligases
$400,000Shao-Cong Sun · University Of Tx Md Anderson Can Ctr · R01 · FY2014 · AI
Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy
$400,000Ze Lu · Optimum Therapeutics, Llc · R44 · FY2009 · CA
Comprehensive Cancer Center Program at Fox Chase
$400,000Jonathan D. Chernoff · Research Inst Of Fox Chase Can Ctr · P30 · FY2022 · CA
SBIR Phase II: Clinical-Scale Suspension Bioreactor for Primary Hematopoietic Culture
$400,000Todd A McAdams · Tissue Therapeutics · · FY2000 · TIP
Mechanism and therapeutic potential of microglia regulation in glioblastoma
$400,000Peiwen Chen · Northwestern University At Chicago · R01 · FY2022 · NS
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$400,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
Development of a novel, RNA-interference-based therapeutic to treat prostate cancer
$400,000Robert Schickel · Nuago Therapeutics Inc · R41 · FY2024 · CA
Regulation and function of nonlymphoid organ CD103 dendritic cells
$400,000Stephanie S Watowich · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · AI
A low-cost topical immunotherapy formulation suitable for treating cervical cancer in low and middle income countries and low-resource settings in the U.S.
$400,000Michael J Shamblott · Morphogenesis, Inc. · R43 · FY2021 · CA
SIRPant Technology for anti-Cancer Immunity
$400,000Nathanael McCurley · Sirpant Immunotherapeutics, Inc. · R42 · FY2021 · CA
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
$400,000Jeffrey A Sosman · Vanderbilt University · R01 · FY2013 · FD
Phase 2 Study of Folfirinox Followed by Ipilimumab/GVAX in Pancreatic Cancer
$400,000Dung T Le · Johns Hopkins University · R01 · FY2015 · FD
Targeting cadherin-11 in pancreatic cancer
$400,000Sivanesan Dakshanamurthy · Diviner Therapeutics, Llc · R41 · FY2022 · CA
SBIR PHASE I - TOPIC 405 - PROJECT TITLE: IN VIVO PHARMACOTYPING OF COMBINATION THERAPY IN PRIMARY BRAIN TUMORSFIRM FIXED PRICE - POP: 09/16/2020 - 0
$400,000Christian Knoopke · Lodestone Biomedical, Llc · N43 · FY2020 · CA
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer
$400,000George Coukos · University Of Pennsylvania · R01 · FY2014 · FD
Phase 2 Study of Folfirinox Followed by Ipilimumab/GVAX in Pancreatic Cancer
$400,000Dung T Le · Johns Hopkins University · R01 · FY2016 · FD
OSTEOGENIC AND IMMUNOMODULATORY PROPERTIES OF DECIDUOUS TOOTH STEM CELLS
$400,000Songtao Shi · University Of Pennsylvania · R01 · FY2016 · DE
Developing a Novel Biologic Therapy to Eradicate Brain Cancer and Brain Metastasis
$400,000Donald Davidson · Creative Biotherapeutics, Llc · R43 · FY2024 · CA
The Immunosuppressive Function of Checkpoint Kinase 2 in Gliomas
$400,000Crismita Clement Dmello · Northwestern University At Chicago · R01 · FY2025 · NS